Pharmacokinetics and Safety of Rupatadine in Hepatic Impairment: A Comparative Study with Matched Controls in Urticaria and Allergic Rhinitis

The primary objective of this study is to evaluate the **pharmacokinetics** and safety profile of rupatadine (10 mg) and its active metabolites in participants with hepatic impairment compared to matched control participants with normal hepatic function. This is clinically relevant as it aims to determine how liver function affects the metabolism and safety of rupatadine, a medication used in the treatment of **urticaria** and **allergic rhinitis**. Understanding these differences is crucial for optimizing dosing regimens and ensuring safe use in patients with compromised liver function.

The clinical trial involves participants diagnosed with **urticaria** and **allergic rhinitis**. The study population includes both male and female subjects, with an age range that encompasses both children and adolescents. The trial population was selected to include a vulnerable population, although specific selection criteria have not been disclosed by the sponsor. The total number of participants has not been provided. Relevant lifestyle considerations such as diet, physical activity, or habits have not been specified. The sponsor has not provided detailed information regarding key inclusion or exclusion criteria for this study.

The clinical trial is designed to evaluate the **pharmacokinetics** and safety of rupatadine (10 mg) and its active metabolites in participants with hepatic impairment compared to matched control participants with normal hepatic function. This study is a Phase 3, randomized, double-blind, controlled trial. The trial is expected to commence recruitment on September 1, 2022, and conclude by January 31, 2023. The study will involve participants diagnosed with **urticaria** or **allergic rhinitis**. The trial will include several key visits: an initial screening visit to assess eligibility, multiple follow-up visits to monitor safety and pharmacokinetic parameters, and a final end-of-study visit to evaluate overall outcomes.

Participants will be involved in the study for the duration of the trial, from the screening visit through to the end-of-study visit, unless early termination is warranted. Conditions that may lead to early termination include adverse events, withdrawal of consent, or any protocol deviations that compromise the integrity of the study. The sequence of study visits is structured to ensure comprehensive data collection and participant safety, with each visit serving a specific purpose in the overall trial design. The trial's methodology is meticulously planned to maintain scientific rigor and ensure the reliability of the results.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available.

Due to the absence of specific details, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring cannot be included. The data does not contain any information about the experimental medication's maximum daily dose, maximum total dose, or maximum treatment period. Furthermore, there is no information on whether the formulation is pediatric or if the product is classified as an orphan drug.

As the source data lacks comprehensive details, it is not possible to provide a complete description of the treatments used in this clinical trial. The information provided is limited to the structure and format required for clinical trial documentation, without specific content regarding the substances involved.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on September 1, 2022, with an estimated end date of January 31, 2023. The efficacy assessment will be conducted through a series of planned evaluations, although specific parameters or endpoints for efficacy evaluation are not detailed in the provided data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The methods and tools for measuring efficacy, as well as the specific timepoints for these assessments, are not specified in the available information. The trial's focus is on gathering robust data to support the evaluation of the treatment's effectiveness within the defined study period.